Vienna, Austria – 11 December 2025: Valvular heart disease, identified through cardiovascular imaging, is common in cancer patients. Interventions to treat valvular heart disease significantly improved survival.1 These findings were presented today at EACVI 2025, the flagship congress of the European Association of Cardiovascular Imaging (EACVI), a branch of the European Society of Cardiology (ESC).
Treatment advances have led to improved survival for patients with cancer. As patients live longer, they are at an increased risk of developing valvular heart disease after successful cancer therapy. Furthermore, it is now well recognised that certain cancer treatments can cause cardiovascular toxicity that may lead to premature morbidity among cancer survivors.2
“Cardiovascular complications are becoming increasingly relevant in older patients after successful cancer therapy. For example, we already know that anthracycline chemotherapy causes heart failure and might lead to tricuspid and mitral valve regurgitation,” explained study presenter, Doctor Maximilian Autherith from the Medical University of Vienna, Austria, who continued: “There is limited evidence to guide the most appropriate management plan for cancer patients with concomitant valvular heart disease, for instance, whether patients benefit from valvular interventions to a similar extent as patients without cancer.” The CESAR study sought to determine the prevalence of valvular heart disease in patients with cancer, describe the frequency of valve interventions and evaluate the impact of interventions on survival.
The observational cohort study included 10,353 adult patients with a confirmed cancer diagnosis who had undergone transthoracic echocardiography within 12 months at a tertiary referral centre. The mean age of the population was 66.2 years and around half (46.6%) were female.
The researchers found that 7.2% of patients had severe valvular heart disease, most commonly tricuspid regurgitation (3.7%), mitral regurgitation (2.6%) and aortic stenosis (2.2%). After adjustment for age, sex, levels of cardiac biomarkers, kidney function and left ventricular function, severe valvular heart disease was found to be an independent predictor of increased mortality (adjusted hazard ratio [HR] 1.46; 95% confidence interval [CI] 1.25–1.71) and cardiovascular death (adjusted HR 2.62; 95% CI 2.00–3.43).
Among those with severe valvular heart disease, 21.5% underwent a surgical or transcatheter intervention. Notably, a valvular intervention was independently associated with improved survival compared to no valvular intervention, resulting in a 72% mortality reduction (adjusted HR 0.28; 95% CI 0.09–0.87) after a median follow-up of 23 months.
Summing up the findings, Doctor Autherith said: “Severe valvular heart disease was prevalent in this selected population of cancer patients who underwent echocardiography. Only a small proportion of patients underwent interventions to treat valvular heart disease, but when they did, the impact on survival was considerable. Our findings highlight the need to refer cancer patients for regular cardiovascular monitoring and also suggest that interventions for valvular heart disease do not need to be withheld in this population. The next steps include further analysis of different administered cancer treatments and performed interventions.”
ENDS
Notes to Editor
Funding: None
Disclosures: Doctor Autherith reports no disclosures related to this study.
References:
1‘Valvular heart disease in cancer patients - prevalence, relevance, and therapeutic management - preliminary results from the CESAR study’ presented during the Role of echocardiography on cardio-oncology session on 11 December at 10:30 to 11:15 CET in Moderated ePoster 1.
2Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229–4361.
ESC Press Office
Tel: +33 6 61 40 18 84
Email: press@escardio.org
Follow European Society of Cardiology News on LinkedIn
About the European Society of Cardiology
The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.
About the European Association of Cardiovascular Imaging (EACVI)
The European Association of Cardiovascular Imaging (EACVI) is a branch of the ESC. It is the world-leading network of cardiovascular imaging experts, welcoming over 8,000 professionals including cardiologists, sonographers, nurses, basic scientists and allied professionals.
EACVI 2025 (#EACVI2025) is a pioneering event that will bring together the fields of echocardiography, cardiovascular magnetic resonance (CMR), cardiac computed tomography (CT) and nuclear cardiology, providing healthcare professionals with a comprehensive and integrated perspective on the cutting-edge technology of cardiovascular imaging.
EACVI 2025 takes place from 11–13 December at VIECON/Messe Wien, Vienna, Austria. Explore the scientific programme.
- Free registration applies to accredited press.
- Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles. Read the ESC media and embargo policy.
- The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid.
- The ESC Press Office decision is final regarding all press registration requests.